Stockscreener 앱 받기
13.98
0.43%
-0.06
시간 외 거래:
13.75
-0.23
-1.65%
전일 마감가:
$14.04
열려 있는:
$14.14
하루 거래량:
58,447
Relative Volume:
0.64
시가총액:
$200.93M
수익:
$1.80M
순이익/손실:
$-241.36M
주가수익비율:
-3.4519
EPS:
-4.05
순현금흐름:
$-197.90M
1주 성능:
-2.44%
1개월 성능:
-9.81%
6개월 성능:
-59.17%
1년 성능:
-29.23%
1일 변동 폭
$13.64
$14.62
1주일 범위
$12.25
$14.77
52주 변동 폭
$10.80
$39.79
인히브릭스 Stock (INBX) Company Profile
명칭
Inhibrx Biosciences Inc
전화
(858) 795-4220
주소
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
INBX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| INBX | 13.98 | 200.93M | 1.80M | -241.36M | -197.90M | -4.05 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
인히브릭스 Stock (INBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | 개시 | SMBC Nikko | Outperform |
| 2021-09-21 | 개시 | JMP Securities | Mkt Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Evercore ISI | Outperform |
모두보기
인히브릭스 주식(INBX)의 최신 뉴스
Trend Tracker for (INBX) - Stock Traders Daily
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com
Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy
Inhibrx Q3 Loss Narrows to $2.84/Share, Maintains $196M Cash for Clinical Programs | INBX Stock News - StockTitan
Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle
(INBX) Trading Signals - Stock Traders Daily
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times
James Sabry on industry-shaping changes in innovation and deal-making - BioCentury
Long Term Trading Analysis for (INBX) - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year - Investing.com Australia
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year By Investing.com - Investing.com South Africa
How To Trade (INBX) - Stock Traders Daily
why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News
INVX underperforms with a -2.86 decrease in share price - US Post News
You might want to take a look at Imunon Inc (IMNN) now - SETE News
Immuneering Corp [IMRX] Shares Fall Approximately -71.25% Over the Year - Knox Daily
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World
Incyte (NASDAQ:INCY) Given “Hold” Rating at Truist Financial - Defense World
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Down 6.9% in August - Defense World
InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World
William Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com
A review of IMNN’s current quarter earnings predictions - US Post News
Its Stock Has Paid Off Big Time For INmune Bio Inc - SETE News
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
IBRX Stock on the Rise: A Promising Investment - The InvestChronicle
Market Watch: Immuneering Corp (IMRX)’s Noteworthy Drop, Closing at 2.78 - The Dwinnex
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
Incyte (NASDAQ:INCY) Receives Market Perform Rating from JMP Securities - Defense World
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
Ratio Review: Analyzing Innovex International Inc. (INVX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
10% Owner Of Impinj Makes $20.00M Buy - Benzinga
Inmune Bio CFO acquires $49k in company stock By Investing.com - Investing.com Canada
Inmune Bio CEO acquires $98k in company stock - Investing.com
Inmune Bio CFO buys $49k in company stock - Investing.com
Inhibrx CEO buys shares worth over $629k - Investing.com India
Inhibrx CEO buys shares worth over $629k By Investing.com - Investing.com Canada
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
How will ImmunityBio Inc’s (IBRX) earnings compare to estimates this quarter? - US Post News
What is IMRX’s price-to-sales ratio telling us about the company’s value? - US Post News
Impinj 10% Owner Trades $20.00M In Company Stock - Benzinga
Take off with ImmunityBio Inc (IBRX): Get ready for trading - SETE News
SEC Form 424B5 filed by INmune Bio Inc. - Quantisnow
Financial Metrics Check: ImmunityBio Inc (IBRX)’s Ratios for Trailing Twelve Months - The Dwinnex
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study - Yahoo Finance
인히브릭스 (INBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):